Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio Sets Target of $712 Million for Hong Kong IPO

publication date: May 27, 2015
3SBio, a China biopharma based in Shenyang, announced it will seek to raise up to $712 million in its Hong Kong IPO, scheduled for early June. The transaction values 3SBio at up to $2.85 billion. That is seven times the company's value when it was taken private from the NASDAQ exchange in the US two years ago. CITIC Private Equity, which helped to fund the privatization, will offer 20% of the offered shares ($176 million), while the rest will be issued by 3SBio. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital